PGM1 and cardiomyopathy: Finally, the in silico drug repurposing identified possible therapeutic options that could target PGM1-deficient cardiomyopathy.<h4>Conclusion</h4>Our data suggests PGM1 is key regulator of cardiomyocyte function, linking sarcomeric Z-disk integrity with mitochondrial metabolism.